Kala Scientific Inc

QIAcard FTA DMPK formats enable microvolume sampling of 10—20 µl per sample and are designed for use with blood. The cards can also be used with colorless fluids such as plasma, cerebrospinal fluid and urine.QIAcard FTA DMPK formatsDrug Metabolism (DM) Pharmacokinetic (PK) studies provide crucial insight into the way drug candidates behave in the body. These studies are a critical step in drug development.Features:DBS microvolume sampling requires only 10—20 µl per sampleConsistent data are obtained through more serial sampling from individual animalsLess reliance on composite dataThe 3-step DBS procedure is more straightforward than the cumbersome centrifugation, isolation and clean-up of plasmaConveys greater analyte stability through on-substrate clean-up, especially for enzyme-sensitive compoundsRoom temperature stability saves on cost of dry ice shipments and allows remote samplingApplication:Drug Metabolism (DM) Pharmacokinetic (PK) studies with sample material derived from blood, plasma, urine, synovial fluid and cerebrospinal fluid analytes.Analysis: Analysis is primarily with HPLC or UHPLC followed by MS/MS detection, direct desorption MS techniques such as DESI. Methanol or aqueous/organic mixtures have been shown to work well for small molecules and aqueous buffers are recommended for proteins. Select a good solvent for the analyte while maintaining compatibility with the HPLC conditions to be used. The choice of DMPK card depends on many factors such as the analyte chemical structure, extraction solvent and analysis workflow.